AC Immune S.A.
ACIU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | 0.27 | 0.18 | -0.36 |
| FCF Yield | 26.71% | -17.19% | -47.49% | -20.20% |
| EV / EBITDA | -4.39 | -5.42 | -1.86 | -3.36 |
| Quality | ||||
| ROIC | -39.95% | -31.57% | -40.49% | -32.65% |
| Gross Margin | -129.12% | -268.93% | -1,433.32% | 0.00% |
| Cash Conversion Ratio | -1.29 | 1.11 | 1.04 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 90.75% | – | -36.59% | -100.00% |
| Free Cash Flow Growth | 206.63% | 18.18% | -9.49% | -11.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 1.45 | 0.42 | 1.03 |
| Interest Coverage | -393.82 | -304.68 | -199.57 | -135.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -44.39 |
| Cash Conversion Cycle | 13.94 | 359.82 | 68.59 | -19.96 |